ePrivacy and GPDR Cookie Consent by TermsFeed Generator

Detail of the clinical trial

Title of the trial A Phase Ib/II, open label study evaluating the safety and pharmacokinetics of GDC-0199 (ABT-199) in combination with Rituximab (R) or Obinutuzumab (G) plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in patients with B Cell non-hodgkin's lymphoma (NHL) and DLBCL
EudraCT number 2013-003749-40
Protocol number GO27878
Sponsor F. Hoffmann- La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland
Indications Hemato-oncology
Diagnosis Non-Hodgkin's Lymphoma and DLBCL
Population in clinical trial Adults (18-65 years)
Elderly ( > 65 years)
Year of receiving the request to Institute (SÚKL) 2014
Date of approval by Institute (SÚKL) 9.2.2015
Date of approval by EC 17.12.2014
Date of initiation CT in ČR 26.11.2015
Date of ending CT in ČR 31.7.2019
Sites Všeobecná fakultní nemocnice v Praze,I. interní klinika - klinika hematologie,U Nemocnice 2,Praha 2,128 08
Fakultní nemocnice Brno ,Interni hematoonkologicka klinika,Jihlavská 20,Brno,625 00
Fakultní nemocnice Ostrava,Klinika hematoonkologie,17. listopadu 1790,Ostrava - Poruba,708 52
FN Hradec Králové,IV. interní hematologická klinika,Sokolska 581,Hradec Králové,500 05

‹‹ Back to list